Investors should buy Lufax as the China-based lending company pivots, according to Sanford C. Bernstein. Analyst Tianjiao Yu initiated coverage of the financial technology stock at outperform. The firm's $2.50 price target for U.S.-listed shares implies 59% upside from where the shares closed Wednesday. "Lufax stock tells what happened in China in the past 3 years — macro weakness, Covid downturn, geopolitics uncertainty, and regulatory tightening on the fintech industry — a fatal blow to profitability in 2023E," Yu said in a note to clients Thursday. "The stock has thus slumped from its IPO prime. We are now turning positive...